|Bid||319.150 x 1800|
|Ask||319.130 x 900|
|Day's Range||317.35 - 320.50|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.99|
|PE Ratio (TTM)||20.77|
|Earnings Date||Jan 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||388.35|
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Biogen’s (BIIB) core growth areas include multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, and neuromuscular disorders. It’s also focused on areas such as pain, ophthalmology, neuropsychiatry, and acute neurology.
In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.
In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million. Its income tax expenses fell YoY to $41.21 million from $177.29 million.
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Biogen Inc (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases.
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.
In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.
Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.
Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.
Should you immediately sell a stock when it breaks out but closes beneath the proper buy point? Not always. Here are some tips on when to sit tight and when to bail early.
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
United Therapeutics (UTHR) generated net revenues of $412.7 million in the third quarter—compared to $445.5 million during the third quarter of 2017, which reflected a decline of ~7% YoY (year-over-year). United Therapeutics’ net revenues during the first nine months of 2018 were $1.25 billion—compared to $1.26 billion during the same period in 2017, which reflected a decline of 1% YoY.
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.